immunotherapy

Personalized T-cell therapy clears metastatic kidney cancer in teen

Researchers at the Hopp Children's Cancer Center Heidelberg have achieved complete remission of advanced, treatment-resistant kidney cancer in an adolescent using a personalized T-cell therapy targeting the PRAME antigen, according to results published August 12 in the New England Journal…

Mayo Clinic identifies protein that cancers use to evade immune system

Mayo Clinic researchers have discovered how cancer cells exploit a protein variant called TRAILshort to shut down the body's immune defenses, a finding that could reshape approaches to immunotherapy across a range of cancers and chronic infections.

J&J says drug combo cut myeloma death risk by 62% in trial

Johnson & Johnson on Wednesday announced that the phase 3 MonumenTAL-6 trial met its primary endpoint, with the combination of Tecvayli (teclistamab) and Talvey (talquetamab) reducing the risk of disease progression or death by 89% and the risk of death…

High-fat diet and gut bacteria boost cancer immunotherapy, study finds

A new study published in Nature on July 8 reveals a counterintuitive finding: a high-fat diet that promotes obesity can, when paired with the right gut bacteria, enhance the effectiveness of cancer immunotherapy. The research demonstrates that the bacterium Lactobacillus…

Harvard AI model predicts which cancer patients will respond to immunotherapy

Researchers at Harvard Medical School have developed an artificial intelligence model called COMPASS that can predict which cancer patients will respond to immune checkpoint inhibitors, a class of drugs that works in only a fraction of those who receive them.…

New CAR-T therapy shows early success against solid tumors

Researchers at the University of Calgary's Charbonneau Cancer Institute and McMaster University have developed GCAR1, a first-in-class chimeric antigen receptor T-cell therapy designed to attack solid tumors — a category of cancer that has largely resisted the immunotherapy approach until…

Nature Medicine retracts lung cancer study on morning immunotherapy

Nature Medicine Springer Nature Group on Tuesday retracted a phase 3 clinical trial that reported patients with advanced lung cancer who received immunotherapy before 3 p.m. lived nearly a year longer than those treated later in the day — removing…

Immunotherapy enabled 3 births in women with early menopause, pilot study finds

A pilot study from Karolinska Institutet has demonstrated that immunotherapy with rituximab can temporarily restore egg maturation in women with autoimmune premature ovarian insufficiency, a condition that typically leads to permanent infertility. Three of ten women treated in the study…